Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres








Gamme d'année
1.
Int. braz. j. urol ; 42(4): 825-837, July-Aug. 2016. tab, graf
Article de Anglais | LILACS | ID: lil-794686

RÉSUMÉ

ABSTRACT Introduction: We investigate the effect of active peptide from Urechis unicinctus (UU) by high temperature/pressure and ultra-wave assisted lysis on erectile dysfunction in streptozotocin-induced diabetic rats. Materials and Methods: Forty 12-week-old Sprague-Dawley rats were used in this study. Diabetes was induced by a one-time intraperitoneal injection of streptozotocin (50mg/kg). One week later, the diabetic rats were randomly divided into four groups: normal control, untreated diabetes control, and groups treated with 100 or 500mg/kg/d UU peptide. Rats were fed with UU peptide by intragastric administration for 8 weeks. After 8 weeks, penile hemodynamic function was evaluated in all groups by measuring the intracavernosal pressure after electrostimulating the cavernous nerve. Nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) activities were measured and endothelial nitric oxide synthase (eNOS) and neuronal NOS (nNOS) protein expression was determined by Western blot. Results: Maximum intracavernosal pressure in diabetic control rats decreased significantly compared to normal control rats, and was increased significantly compared to untreated diabetic rats after UU peptide supplementation. Treatment with the higher dose of UU peptide significantly increased the NO and cGMP levels compared with the diabetic control group. Decreased activity and expression eNOS and nNOS were found in the diabetic rats compared with the normal control group. Decreased eNOS and nNOS in diabetic rats were improved by UU peptide administration. Conclusions: Active peptide from UU ameliorates erectile function in a streptozotocin induced diabetic rat model of erectile dysfunction.


Sujet(s)
Animaux , Mâle , Rats , Peptides/pharmacologie , Diabète expérimental/complications , Dysfonctionnement érectile/traitement médicamenteux , Annelida/composition chimique , Pénis/effets des médicaments et des substances chimiques , Peptides/analyse , Peptides/usage thérapeutique , Température , Répartition aléatoire , Cellules cultivées , Rat Sprague-Dawley , Streptozocine , Diabète expérimental/induit chimiquement , Dysfonctionnement érectile/étiologie , Dysfonctionnement érectile/physiopathologie
2.
Int. braz. j. urol ; 38(6): 833-841, Nov-Dec/2012. graf
Article de Anglais | LILACS | ID: lil-666025

RÉSUMÉ

Objectives

To evaluate the effect of mesenchymal stem cells (MSCs) and MSCs mixed with Matrixen as a cell carrier on the erectile dysfunction caused by bilateral cavernous nerve crushing injury. Materials and Methods

White male Sprague-Dawley rats were divided into 4 groups: sham-operated control group (n = 5), bilateral cavernous nerve crushing group (BCNC group, n = 10), BCNC administered with MSCs group (n = 10,1×106 in 20 µL), BCNC administered with Matrixen group (n = 10.1×106 in 20 µL), BCNC administered with MSCs/Matrixen group (n = 10.1×106 in 20 µL). After functional assessment at 4 weeks, major pelvic ganglion (MPG) and penile tissue were collected. Immunofluorescent staining of MPG was performed with PKH26 and Tuj1. Western blot analysis of endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS) were done in corpus cavernosum. Results

ICP/MAP ratios of BCNC with MSCs and MSCs/Matrixen groups were significantly increased compared with BCNC and BCNC with Matrixen group. Moreover, ICP/MAP ratios of MSCs/Matrixen group were significantly increased compared with BCNC with MSCs group. In MPG, the more implantation of MSCs and increased expression of nerve cells were observed in MSCs/Matrixen group compared with BCNC with MSCs group. Significant increase expression of eNOS and nNOS was also noted in BCNC with MSCs/Matrixen group. Conclusion

The erectile function was more preserved in MSCs/Matrixen group compared with the administration of MSCs alone in the rats with bilateral cavernous nerve crushing injury. Therefore, we consider that the use of transplant cell carrier such as Matrixen may help the implantation of MSCs and improve the therapeutic effect of MSCs. .


Sujet(s)
Animaux , Mâle , Rats , Dysfonctionnement érectile/thérapie , Transplantation de cellules souches mésenchymateuses , Pénis/innervation , Technique de Western , Dysfonctionnement érectile/étiologie , Technique d'immunofluorescence , Modèles animaux , Nitric oxide synthase type I/analyse , Nitric oxide synthase type III/analyse , Érection du pénis/effets des médicaments et des substances chimiques , Pénis/effets des médicaments et des substances chimiques , Rat Sprague-Dawley , Résultat thérapeutique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE